Skip to main content

Atara Biotherapeutics, Inc.

ATRA
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001604464

In the last 90 days, Atara Biotherapeutics, Inc. insiders filed 1 open-market purchase and 1 sale; 36 institutions reported holding it in 13F filings for Q2 2026, worth $51.3M in total; no superinvestor holds it.

Q3 2023 vs. Q2 2023

How the institutions holding Atara Biotherapeutics, Inc. changed between Q2 2023 and Q3 2023.

All holders in Q3 2023All holders in Q2 2023

13F holders of ATRA: Q2 2023 compared with Q3 2023
MeasureQ2 2023Q3 2023Change
Holders118109−9
Shares90.5M88.2M−2.27M (−2.5%)
Value$145.8M$130.5M−$15.3M (−10.5%)

New holders (11)

Institutions that held Atara Biotherapeutics, Inc. at the end of Q3 2023 but not at the end of Q2 2023.

Institutions new to ATRA in Q3 2023
InstitutionSharesValue% of portfolio
Driehaus Capital Management LLC589,950$873.1K0.01%
Arctis Global LLC397,046$587.6K0.33%
Group One Trading, L.P.64,091$94.9K0.00%
SG Americas Securities, LLC38,743$57.0K0.00%
Captrust Financial Advisors18,015$26.7K0.00%
Engineers Gate Manager LP14,120$20.9K0.00%
Dynamic Technology Lab Private Ltd11,927$17.0K0.00%
FNY Investment Advisers, LLC3,000$4.00K0.00%
Toronto Dominion Bank397$5880.00%
Comerica Bank108$1600.00%
NewSquare Capital LLC39$580.00%

Sold out (20)

Institutions that held Atara Biotherapeutics, Inc. at the end of Q2 2023 and filed for Q3 2023 without it.